Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the eight analysts that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, five have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $13.60.Get Orchestra BioMed alerts:A number of research firms have recently commented on OBIO. Barclays cut their price objective on Orchestra BioMed from $12.00 to $11.00 and set an "overweight" rating for the company in a research report on Wednesday, November 12th. Cowen began coverage on shares of Orchestra BioMed in a report on Wednesday, December 10th. They issued a "buy" rating for the company. TD Cowen began coverage on shares of Orchestra BioMed in a research report on Wednesday, December 10th. They set a "buy" rating and a $15.00 price objective for the company. Chardan Capital reaffirmed a "buy" rating and set a $20.00 price objective on shares of Orchestra BioMed in a report on Thursday, November 13th. Finally, Weiss Ratings reissued a "sell (e+)" rating on shares of Orchestra BioMed in a research note on Wednesday, October 8th.Get Our Latest Research Report on Orchestra BioMedInstitutional Trading of Orchestra BioMedInstitutional investors have recently made changes to their positions in the company. Alyeska Investment Group L.P. acquired a new position in Orchestra BioMed in the 3rd quarter valued at $3,386,000. Pathstone Holdings LLC purchased a new stake in shares of Orchestra BioMed during the third quarter worth $2,495,000. Vanguard Group Inc. raised its position in shares of Orchestra BioMed by 28.0% in the third quarter. Vanguard Group Inc. now owns 1,481,875 shares of the company's stock valued at $3,675,000 after buying an additional 324,558 shares during the last quarter. AMH Equity Ltd purchased a new position in shares of Orchestra BioMed in the third quarter worth about $412,000. Finally, Knott David M Jr purchased a new position in shares of Orchestra BioMed in the second quarter worth about $268,000. 53.20% of the stock is owned by institutional investors and hedge funds. Orchestra BioMed Trading Up 3.9%Shares of Orchestra BioMed stock opened at $4.31 on Friday. The firm has a 50-day simple moving average of $4.35 and a two-hundred day simple moving average of $3.39. The company has a debt-to-equity ratio of 0.32, a quick ratio of 4.72 and a current ratio of 4.73. Orchestra BioMed has a fifty-two week low of $2.20 and a fifty-two week high of $6.16. The company has a market cap of $243.39 million, a P/E ratio of -2.37 and a beta of 0.63. Orchestra BioMed (NASDAQ:OBIO - Get Free Report) last posted its earnings results on Monday, November 10th. The company reported ($0.40) EPS for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.02). The business had revenue of $0.86 million for the quarter, compared to analyst estimates of $0.74 million. Orchestra BioMed had a negative net margin of 2,665.05% and a negative return on equity of 320.09%. As a group, equities analysts predict that Orchestra BioMed will post -1.66 earnings per share for the current fiscal year. Orchestra BioMed Company Profile (Get Free Report)Orchestra BioMed, Inc NASDAQ: OBIO is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company's research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed's pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis. Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.Featured ArticlesFive stocks we like better than Orchestra BioMedDo not delete, read immediatelyThe $100 Trillion AI Story No One Is Telling YouIf You Keep Cash In A U.S. Bank Account… Read This NOWBut this $2 Gold Stock Before May 20, 20263 Overlooked Deductions to Help Potentially Minimize Capital Gains TaxThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Orchestra BioMed Right Now?Before you consider Orchestra BioMed, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Orchestra BioMed wasn't on the list.While Orchestra BioMed currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here